Vyfemla is a birth control preparation prescribed for pregnancy prevention. It is a monophasic medication containing two hormones – progestin and estrogen.
Indications for use
- Uterine hypoplasia.
Mechanism of action
Vyfemla is a contraceptive agent. It is combined low dose estrogen-progestin drug. It inhibits pituitary secretion of gonadotropic hormones. The contraceptive effect of the drug is realized due to the blocking effect of the progestin and estrogen components on the hypothalamic-pituitary-ovarian system. The estrogen component is the highly effective oral drug – ethinyl estradiol, a synthetic analog of the follicular hormone estradiol, which participates in the menstrual cycle with the yellow body hormone (progestin, gestagen). The gestagen component of the drug is norethisterone, which inhibits the synthesis of LH and FSH by the pituitary and thus, blocks ovulation. Due to the combination of estrogen with gestagen, the drug under the appropriate schemes of use can both stimulate and delay menstruation and help stop the acyclic uterine bleeding.
Mode of application and dosage
Vyfemla should be taken on the first day of the menstrual cycle. On this day, it is necessary to take one hormone-containing pill, which is marked with the corresponding day of the week. Then take the pill in the order specified on the blister. You can start taking the drug on the 2nd-5th day of the menstrual cycle, but in this case, the barrier method of contraception (for example, a condom) must be used during the first 7 days of taking active tablets.
Vyfemla is contraindicated in the following health conditions:
- breast cancer (suspected as well);
- pregnancy (including the suspected, except for cases of miscarriage);
- cholestatic jaundice of pregnant women in the anamnesis;
- jaundice (including in the anamnesis);
- acute hepatic dysfunctions (including benign and malignant neoplasms);
- acute thrombophlebitis or thromboembolism;
- bleeding from the urinary tract of unclear etiology;
- metrorrhagia of unclear genesis;
- vaginal bleeding of an unknown genesis;
- puberty period.
Take this birth control drug with caution in the following cases:
- bronchial asthma;
- congestive cardiac failure;
- arterial hypertension;
- renal failure;
- seizures, or other abnormalities of the central nervous system (including in the medical history);
- diabetes mellitus;
- liver disease (inclusively of the anamnesis);
- history of thrombophlebitis;
- thromboembolism in the medical history.
- Tenderness of the mammary glands;
- Weight gain;
- Changes in libido;
- Mood shifts;
- Eyelid edema;
- Skin rash;
- Visual impairment;
- Hearing loss;
- Generalized itching;
- Intermenstrual bleeding.
Barbiturates, some antiepileptic drugs (carbamazepine, phenytoin) are able to enhance the metabolism of the estrogen and progestin. The decrease of the effective concentration is observed with simultaneous use with certain antibiotics (ampicillin, rifampicin), which is associated with a change in the intestinal microflora. The contraceptive effectiveness decreases in the case of regular excessive use of ethanol. When taking gestagen-estrogen drugs, it may be necessary to correct the dosage regimen for hypoglycemic drugs.
What if I miss a dose?
If the patient has forgotten to take the next pill, then the missed tablet should be taken as soon as possible, in which case, additional methods of contraception should be applied. Before the start of treatment, it is necessary to exclude the presence of malignant neoplasms.
Vyfemla and pregnancy
Vyfemla is contraindicated during pregnancy.
If pregnancy occurs during the period of taking the drug, then it should be stopped immediately. The information available regarding the use of the drug during pregnancy is too limited to draw conclusions about the negative effects on pregnancy, the health of the fetus and the newborn.
The drug is contraindicated for use in breastfeeding women.